The Scientist profiles Mireille Gingras' company, HUYA Bioscience International, which focuses on finding early-stage drug compounds from China. HUYA, the article says, has a codevelopment model in which it licenses the compounds for development for Western markets and the Chinese company retains the rights to the Chinese market.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.